Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epigenetics in multiple myeloma: From mechanisms to therapy
Mohammad Alzrigat, Alba Atienza Párraga, Helena Jernberg‐Wiklund
Seminars in Cancer Biology (2017) Vol. 51, pp. 101-115
Closed Access | Times Cited: 76

Showing 26-50 of 76 citing articles:

1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma
Travis S. Johnson, Parvathi Sudha, Enze Liu, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
Takayuki Saitoh, Tsukasa Oda
Cancers (2021) Vol. 13, Iss. 3, pp. 504-504
Open Access | Times Cited: 20
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma
Yanmeng Wang, Catharina Muylaert, Arne Wyns, et al.
Haematologica (2023)
Open Access | Times Cited: 7
Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity
Mohammad Alzrigat, Helena Jernberg‐Wiklund, Jonathan D. Licht
Epigenomes (2018) Vol. 2, Iss. 3, pp. 16-16
Open Access | Times Cited: 23
Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles
Mahmoud Dabbah, Osnat Jarchowsky-Dolberg, Oshrat Attar‐Schneider, et al.
Carcinogenesis (2019) Vol. 41, Iss. 1, pp. 100-110
Open Access | Times Cited: 20
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 12
Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma
Larissa Haertle, Santiago Barrio, Umair Munawar, et al.
Clinical Cancer Research (2022) Vol. 29, Iss. 1, pp. 279-288
Open Access | Times Cited: 11
Erratum: Multiple myeloma BM-MSCs increase the tumorigenicity of MM cells via transfer of VLA4-enriched microvesicles
Mahmoud Dabbah, Osnat Jarchowsky-Dolberg, Oshrat Attar‐Schneider, et al.
Carcinogenesis (2019) Vol. 41, Iss. 1, pp. 122-122
Open Access | Times Cited: 16
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib
Li Xu, Juan Feng, Hailong Tang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 4
Open Access | Times Cited: 15
Frequent upregulation of G9a promotes RelB-dependent proliferation and survival in multiple myeloma
Xi Yun Zhang, Deepa Rajagopalan, Tae‐Hoon Chung, et al.
Experimental Hematology and Oncology (2020) Vol. 9, Iss. 1
Open Access | Times Cited: 15
NSD2 as a Promising Target in Hematological Disorders
Alba Azagra, César Cobaleda
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11075-11075
Open Access | Times Cited: 9
The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
Sara Ovejero, Elena Viziteu, Laure Dutrieux, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway
Caroline Dafflon, Swann Gaulis, Louise Barys, et al.
Oncotarget (2020) Vol. 11, Iss. 11, pp. 956-968
Open Access | Times Cited: 14
Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma
Tiziana Bruno, Francesca De Nicola, Giacomo Corleone, et al.
Blood Advances (2020) Vol. 4, Iss. 22, pp. 5616-5630
Open Access | Times Cited: 13
Pathoepigenetics: The Role of Epigenetic Biomarkers in Disease Pathogenesis
Ramón Cacabelos
Elsevier eBooks (2019), pp. 139-189
Closed Access | Times Cited: 12
Increased Expression of SETDB1 Predicts Poor Prognosis in Multiple Myeloma
Jing Xiang, Xiaotong Chen, Mengping Chen, et al.
BioMed Research International (2022) Vol. 2022, pp. 1-19
Open Access | Times Cited: 8
Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer
Xia Li, Jingjing Li, Jie Li, et al.
BMC Genomics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation
Palmiro Poltronieri
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 4, pp. 841-876
Open Access | Times Cited: 1
The SAGA acetyltransferase module is required for the maintenance of MAF and MYC oncogenic gene expression programs in multiple myeloma
Ying-Jiun C. Chen, Govinal Badiger Bhaskara, Yue Lu, et al.
Genes & Development (2024) Vol. 38, Iss. 15-16, pp. 738-754
Open Access | Times Cited: 1
Role of Polycomb Complexes in Normal and Malignant Plasma Cells
Emmanuel Varlet, Sara Ovejero, Anne‐Marie Martinez, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 8047-8047
Open Access | Times Cited: 9
YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma
Qingqing Yin, Xianjuan Shen, Honglei Xu, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2023) Vol. 64, Iss. 6, pp. 1161-1174
Closed Access | Times Cited: 3
As4S4 Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway
Di Wu, Wei Dong, Kun Fang, et al.
Technology in Cancer Research & Treatment (2019) Vol. 18
Open Access | Times Cited: 8
Systematic discrimination of the repetitive genome in proximity of ferroptosis genes and a novel prognostic signature correlating with the oncogenic lncRNA CRNDE in multiple myeloma
Jiading Qin, Amit Sharma, Yulu Wang, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 5
Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
Rikio Suzuki, Yuka Kitamura, Yoshihiko Nakamura, et al.
Oncotarget (2020) Vol. 11, Iss. 44, pp. 3984-3997
Open Access | Times Cited: 7
Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression
Ying‐Mei Lu, Yiyue Feng, Li Zhao, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113908-113908
Closed Access | Times Cited: 7

Scroll to top